Summary
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
AtriCure, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 129 | $3,954.25 | $4,524.03 | $569.78 | 14.41% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 113,330 | $4.29M | $3.97M | -$323,748.22 | -7.54% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 41,547 | $1.35M | $1.46M | $103,109.67 | 7.63% |
| BG Bart Gancher Intech Investment Management LLC | 11,026 | $354,275.86 | $386,461.3 | $32,185.44 | 9.08% |
 Bridgewater Associates LP Bridgewater Associates LP | 33,517 | $956,240 | $1.17M | $217,220.34 | 22.72% |
AtriCure, Inc. (ATRC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AtriCure, Inc. ever had a stock split?
AtriCure, Inc. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Michael H. Carrel CEO | NASDAQ (NMS) Exchange | 04963C209 CUSIP |
| US Country | 1,350 Employees | - Last Dividend | - Last Split | 5 Aug 2005 IPO Date |
Overview
AtriCure, Inc. is a medical device company that specializes in the development, manufacturing, and sales of surgical tools designed for the ablation of cardiac tissue, the exclusion of the left atrial appendage, and the temporary blocking of pain through peripheral nerve ablation. The company operates on a global scale, with a significant presence in the United States, Europe, the Asia-Pacific region, and other international markets. Since its incorporation in 2000, AtriCure has established its headquarters in Mason, Ohio, and has expanded its market reach through a combination of direct sales staff and independent distributors. AtriCure's mission is centered around innovating cardiac care, particularly focusing on solutions to address atrial fibrillation and related conditions.
Products and Services
AtriCure boasts a diverse portfolio of products and services designed to support cardiac surgery and pain management. The company’s offerings include:
- Isolator Synergy Clamps: These clamps are single-use, disposable products utilizing radio frequency to facilitate surgical ablation of cardiac tissue. They represent a cornerstone of AtriCure’s ablation solutions.
- MAX Pen Device: A multifunctional pen that enables surgeons to diagnose cardiac arrhythmias, perform temporary cardiac pacing, sensing, stimulation, and ablate cardiac tissue using a single device. This innovative approach streamlines procedures by consolidating functionalities.
- Coolrail Device: Designed to create longer linear lines of ablation, the Coolrail device simplifies the process of cardiac tissue ablation, making it more efficient for surgeons to perform complex procedures.
- cryoICE Cryoablation System: This system allows for the creation of linear ablations of varying lengths through cryoablation, offering an alternative modality to treat cardiac arrhythmias.
- EPi-Sense Systems: A cutting-edge solution for the treatment of persistent atrial fibrillation, the EPi-Sense System is a single-use device that represents AtriCure’s commitment to addressing complex cardiac conditions.
- cryoSPHERE Probe: Specifically designed for pain management, the cryoSPHERE probe applies cryothermic energy to targeted peripheral nerves in the ribcage to provide temporary relief from pain.
- AtriClip System: This system features an implantable device paired with a single-use disposable applier, intended for the exclusion of the left atrial appendage, a procedure often required in the management of atrial fibrillation.
- LARIAT System: As a suture-based solution for soft-tissue closure, the LARIAT System exemplifies AtriCure’s innovative approach to post-procedural care, offering a novel method for securing tissue after surgical interventions.
- Additional Tools: AtriCure also supplies a range of supplementary tools such as the Lumitip dissectors for tissue separation, Glidepath guides for clamp placement, Subtle Cannula’s to facilitate access for EPi-Sense catheters, and various reusable instruments for cardiac surgery, underlining the company’s comprehensive approach to cardiac care solutions.
